In The News

Wall Street Journal - 12/09/2015
Private-equity firm Cerberus Capital Management has invested $105 million in PaxVax Inc., a maker of specialty vaccines, Amy Or reports for Dow Jones VentureWire. The private-equity firm will hold a majority stake of the company’s shares after the...
11/30/2015
PaxVax, founded in 2007, is an American specialty vaccine company with its headquarters in Redwood City, California. In 2014 the life sciences firm acquired PaxVax Berna in Thörishaus in the Canton of Bern. As a result of this purchase the company...
09/01/2015
This July, PaxVax celebrated its first anniversary since expanding to Switzerland. It was the perfect time to talk to the company's CEO, Nima Farzan, about the many business decisions that went into this important acquisition. On a recent afternoon...
01/15/2015
PaxVax entered the M&A arena last summer, nabbing typhoid vaccine Vivotif from Johnson & Johnson subsidiary Crucell. And it's not stopping there, CEO Ken Kelley says. The California company has another specialty travel vaccine deal coming...
09/03/2014
September 3, 2014 – VaccineNation, a leading provider of news and analysis on the vaccine industry, today announced their ranking of the fifty most influential people in vaccines. From a pool of more than 100 nominations, the publication and its...
San Francisco Business Times - 07/03/2014
A single-dose experimental cholera vaccine from PaxVax Inc. passed a key test toward becoming the only vaccine for U.S. residents traveling abroad.
Democrat & Chronicle - 05/19/2014
A California outfit, PaxVax, is conducting the trial as it seeks approval from the Food and Drug Administration to market this version to American travelers heading to high-risk areas.
Popular Science - Under the Microscope - 12/11/2013
In any relationship, whether between two people or between individuals and germs, there are inevitably matches that are simply tragic...An American company called PaxVax has just announced that their oral, single dose and rapid-acting travellers’...
San Diego Business Journal - 10/14/2013
San Diego vaccine company PaxVax Inc. has begun a phase 3 round of clinical trials, conducting what’s called a “challenge study” among healthy volunteers ages 18 to 49 at three research hospitals — University of Maryland, University of Vermont and...
BioWorld Today - 09/09/2013
Paxvax Inc.’s just-begun Phase III effort with PXVX0200 could lead to the first cholera vaccine approved for marketing in the U.S., and the company could become the first to gauge the resale value of the FDA’s priority review voucher (PRV), an...

Pages